Medtronic clears cardiac software milestones. Medtronic stock gains 1.43 percent.

Published on 10/02/2026 at 14:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fiscal 2027 first-quarter revenue reached USD 9.76 billion, up 13.70 percent. Medtronic stock costs EUR 77.56 on October 2, 2026 after EUR 76.47.

Flatlay mit Aktienzertifikat, ISIN-Karte, Stethoskop und medizinischen Utensilien — Medtronic plc (ISIN IE00BTN1Y115) Flatlay kombiniert Aktienzertifikat, ISIN-Karte, Stethoskop und medizinische Utensilien, Illustration mit AI erstellt.

Medtronic (ISIN IE00BTN1Y115) was trading at EUR 77.56 at Lang & Schwarz on October 2, 2026 at 2:17 p.m. CEST, up 1.43 percent versus the prior close of EUR 76.47. On September 30, 2026, Medtronic announced FDA clearance and CE Mark approval for Affera Prism-2 Mapping Software and CE Mark approval for the PulseSelect ProxBox Adapter with Proximity Indicator software.

Cardiac software expands the portfolio

The regulatory milestones add new mapping and tissue-proximity functions to Medtronic's cardiac ablation platforms. Prism-2 creates three-dimensional maps of electrical activity during procedures, while ProxBox provides real-time impedance-based feedback before pulsed-field ablation energy is delivered, according to the company's September 30 release.

The announcement matters because Medtronic is extending software around existing hardware rather than relying only on new device launches. The company said the PulseSelect system is used in more than 60 countries, giving the software rollout a broad commercial footprint.

Revenue beat gives the stock context

Medtronic's first-quarter fiscal 2027 revenue reached USD 9.76 billion, up 13.70 percent year over year and ahead of the USD 9.55 billion consensus estimate, according to Yahoo Finance on September 17, 2026. Adjusted earnings per share reached USD 1.45, above the USD 1.39 consensus estimate.

The growth was broad across the business: Cardiovascular revenue rose 19.50 percent, Diabetes revenue increased 16.90 percent, Neuroscience revenue advanced 10.30 percent and Medical Surgical revenue grew 10.00 percent in the first quarter of fiscal 2027. That breadth gives the cardiac software news a stronger operating backdrop than a single-product update.

Analyst target stays at USD 110

TD Cowen reiterated a Buy rating and maintained its USD 110.00 price target on September 30, 2026, as Investing.com reported. The analyst cited potential electrophysiology market-share gains and a favorable cardiac and vascular product mix.

TradingView lists November 24, 2026 as Medtronic's next earnings date, with a second-quarter fiscal 2027 revenue estimate of USD 9.48 billion and adjusted earnings-per-share estimate of USD 1.33, providing the next scheduled test for the growth outlook.

Medtronic stock trades in Europe

Medtronic's Lang & Schwarz quote stood at EUR 77.56 on October 2, 2026 at 2:17 p.m. CEST, with the EUR 76.47 prior close dated October 1, 2026. The structured market data showed a USD 110.6 billion market capitalization and a USD 73.31 to USD 106.33 52-week range as of October 2, 2026, values that describe the NYSE listing separately from the euro reference quote.

The further course of trading is shown by the continuously updated real-time quote of Medtronic stock.